| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01349192 Details | 2017-05-15 Interventional | 2 | 47 | Chlorhexidine Chlorhexidine g… Minocycline Mupirocin Rifampin Sulfamethoxazol… Trimethoprim Cystic Fibrosis Fibrosis Staphylococcal … Methicillin-res… | Interim review showed a statistically significant treatment effect and the DMC recommended that
the study be stopped with ongoing follow-up of enrolled subjects The study was completed prior to reaching the pre-specified number of participants as the Data Safety Monitoring committee observed that efficacy had been reached. | |||
| NCT00863434 Details | 2017-05-15 Interventional | 2 | 2 | Clofarabine Cytarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Neoplasm, Resid… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Recurrent Adult… | - - | |||
| NCT00706914 Details | 2017-05-15 Interventional | 2 | 156 | Formoterol Fuma… Lung Diseases Pulmonary Disea… | Actual sample size of 156 was sufficient to estimate the clinical outcomes. Due to early termination of the study, the actual sample size is different from the study design (200 patients) Actual sample size was 156, but because this was an exploratory study, this was considered sufficient to estimate the clinical outcomes | |||
| NCT00082017 NCT00085319 Details | 2017-05-15 Interventional | 2 | 20 | 7-hydroxystauro… Lymphoma Lymphoma, Large… Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphoma, Large… | IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND. - | |||
| NCT01746940 Details | 2017-05-12 Interventional | 3 | 159 | Cocaine Pharmaceutical … Diagnostic Procedures and … of the Nasal Ca… | Trial operational issues. - | |||
| NCT01641939 2012-000660-22 Details | 2017-05-12 Interventional | 2/3 | 415 | Ado-Trastuzumab… Maytansine Taxane Trastuzumab Stomach Neoplas… Gastric Cancer | - The study was terminated by the Sponsor as the primary analysis results did not meet the primary endpoint. | |||
| NCT02088450 Details | 2017-05-11 Interventional | 2 | 4695 | Nitrendipine Hypertension Isolated Systol… Systolic Murmur… | - - | |||
| NCT01587963 Details | 2017-05-11 Interventional | 2 | 11 | Ascorbic Acid Critical Illnes… Shock | PI's add. responsibilities and time commitment prevent him from completing trial Early termination leading to small number of subjects analyzed | |||
| NCT01464788 Details | 2017-05-11 Interventional | 2 | 90 | Argatroban Tissue Plasmino… Ischemic Stroke Stroke | The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of
embolectomy clinical trials. Study limitations include the open-label design that was necessary due to prohibitive costs of placebo manufacture and sham aPTT tests. Given that vessel imaging was not mandatory, a meaningful analysis of early recanalization rates was not possible. | |||
| NCT01417104 NCT01123629 Details | 2017-05-11 Interventional | 2/3 | 71 | Aliskiren Atherosclerosis | Safety concerns with approved medication identified in an unrelated trial - | |||
| NCT01349114 Details | 2017-05-11 Interventional | 4 | 21 | Aliskiren Hypertension Prehypertension Diabetes Pre-hypertensio… | Sponsor requested termination. Early termination leading to smaller number of subjects analyzed then anticipated, no adverse effects within the aliskiren group | |||
| NCT00449163 Details | 2017-05-11 Interventional | 2 | [1 Refs] | 25 | Bevacizumab Floxuridine Irinotecan Leucovorin Levoleucovorin Colorectal Neop… Colorectal Canc… | Study terminated by University of Miami Institutional Review Board A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board. | ||
| NCT03009799 Details | 2017-05-10 Interventional | 2 | 0 | Carboxymethylce… Conjunctivitis Adenoviral Conj… | Study stopped following management decision - | |||
| NCT00936520 Details | 2017-05-10 Interventional | 1 | 30 | Lifitegrast Macular Edema Diabetic Macula… Pars Plana Vitr… | Preliminary analysis showed little or no bioactivity. - | |||
| NCT03117166 Details | 2017-05-09 Interventional | 1/2 | 19 | Lidocaine Pain | multidisciplinary participation could not be overcome. - | |||
| NCT02289495 Details | 2017-05-09 Interventional | 1 | 24 | GSK-2838232 Ritonavir Acquired Immuno… HIV Infections Infection, Huma… | - - | |||
| NCT01610999 Details | 2017-05-09 Interventional | 1 | 7 | Plerixafor Leukemia, Lymph… Multiple Myelom… Chronic Lymphoc… Lymphoma | Unavailability of study article - | |||
| NCT01483274 Details | 2017-05-09 Interventional | 1 | 0 | Vaccines Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… | Adult patient population barriers. - | |||
| NCT01248858 Details | 2017-05-09 Interventional | 1 | 69 | Trametinib Cancer | The reason for termination was lack of tolerability and efficacy of the combination treatment - | |||
| NCT01031953 NCT00939302 Details | 2017-05-09 Interventional | 1/2 | 34 | Aprepitant Fosaprepitant Nausea Vomiting Breakthrough Na… Unspecified Adu… | Drug contract timelines and inadequate enrollment Missing data did affect results for the 24 hour mark Lack of control group to measure possible neurokinin-1 antagonist (NK1a) inhibition |